0001104659-21-043650.txt : 20210330 0001104659-21-043650.hdr.sgml : 20210330 20210330074848 ACCESSION NUMBER: 0001104659-21-043650 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210330 DATE AS OF CHANGE: 20210330 EFFECTIVENESS DATE: 20210330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-393952 FILM NUMBER: 21783652 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 D 1 primary_doc.xml X0708 D LIVE 0001534248 Chemomab Therapeutics Ltd. KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 ISRAEL 6158002 +972-77-331-0156 ISRAEL None Anchiano Therapeutics Ltd. BioCancell Ltd. Corporation true Adi Mor George 15 Kafrisin St. Tel Aviv L3 ISRAEL 6901658 Executive Officer Director Sigal Fatal 16 Kanfey Nesharim St. Ramat Gan L3 ISRAEL 5235716 Executive Officer Arnon Aharon 12 Yavne St. Tel Aviv L3 ISRAEL 6579116 Executive Officer Stephen P Squinto 930 5th Ave New York NY NEW YORK 10021 Director Moses Charles Alan C/O CHEMOMAB THERAPEUTICS LTD. Kiryat Atidim Building 7 Tel Aviv L3 ISRAEL 6158002 Director Claude Nicaise 319 Redstone Drive Cheshire CT CONNECTICUT 06410 Director Nissim Darvish C/O CHEMOMAB THERAPEUTICS LTD. KIRYAT ATIDIM, BUILDING 7 Tel Aviv L3 ISRAEL 6158002 Director Joel Michael Maryles 5 Atzmon St. Hashmonaim L3 ISRAEL 7312700 Director Neil Harris Cohen 1400 E, STE 14-105 1 KENDALL SQ, BLDG Cambridge MA MASSACHUSETTS 02139 Director Biotechnology $25,000,001 - $100,000,000 06b false 2021-03-16 false true true true true The Issuer completed a business combination transaction on March 16, 2021, and as a condition thereto the Issuer consummated a private placement transaction, of which is being reported in this Form D. 0 Oppenheimer & Co. Inc. 249 None None 85 BROAD STREET NEW YORK NY NEW YORK 10004 CA CALIFORNIA CT CONNECTICUT IL ILLINOIS MD MARYLAND MA MASSACHUSETTS NV NEVADA NJ NEW JERSEY NY NEW YORK OR OREGON TX TEXAS false 45446544 45446544 0 false 26 1579794 0 0 false Chemomab Therapeutics Ltd. /s/ Adi Mor George Adi Mor George Chief Executive Officer 2021-03-30